The Pituitary Center, Department of Medicine, Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):314-21. doi: 10.1097/MED.0b013e32835430ed.
To discuss the multiple forms of hypophysitis, the various methods of classification, the recent findings in pituitary autoimmunity and novel methods of treating resistant or recurrent hypophysitis. (January 2010-December 2011).
Multiple novel presentations of hypophysitis have been described including cytotoxic T-lymphocyte antigen-4 antibody-related hypophysitis, an adverse event associated with a novel treatment for cancer, Food and Drug Administration approved for use in the treatment of metastatic melanoma. A rare, but newly described entity of immunoglobulin G4 related plasmacytic hypophysitis has been described and reviewed. Multiple investigations addressing the role of autoimmunity in the diagnosis and pathogenesis of hypophysitis have been reported with positive antipituitary antibodies found in patients with autoimmune hypophysitis, other autoimmune diseases, and nonimmune-related pituitary diseases. Several case series and case reports present new associations with concomitant diseases and novel therapy for cases requiring treatment when standard therapy fails or is contraindicated.
Hypophysitis is a rare disease with multiple subtypes. The description of hypophysitis related to cytotoxic T-lymphocyte antigen-4 antibody treatment is one of the first descriptions of hypophysitis triggered by medication. As the use of this novel treatment for cancer increases, so must our awareness of immune-related adverse effects and their treatment. Pituitary autoimmunity is a challenging field with multiple discoveries reported to help further our understanding of the disease and assist in diagnosis. Insufficient sensitivity and specificity of the currently reported methods prevents recommending measurement of antipituitary antibodies as standard of care in the diagnosis of hypophysitis. The treatment of hypophysitis remains controversial with recommendations ranging from hormonal replacement to newly described therapies such as azathioprine and radiation.
讨论多种形式的垂体炎、分类的各种方法、最近在垂体自身免疫方面的发现以及治疗抵抗或复发性垂体炎的新方法。(2010 年 1 月-2011 年 12 月)。
描述了多种新的垂体炎表现形式,包括细胞毒性 T 淋巴细胞抗原-4 抗体相关的垂体炎,这是一种与新型癌症治疗相关的不良事件,美国食品和药物管理局已批准该疗法用于治疗转移性黑色素瘤。一种罕见但最近描述的免疫球蛋白 G4 相关浆细胞性垂体炎也已被描述和综述。已有多项研究探讨了自身免疫在垂体炎的诊断和发病机制中的作用,在自身免疫性垂体炎、其他自身免疫性疾病和非免疫性垂体疾病患者中发现了抗垂体抗体阳性。有几个病例系列和病例报告介绍了同时存在的疾病和新的治疗方法的新关联,这些方法用于标准治疗失败或禁忌时需要治疗的病例。
垂体炎是一种罕见的疾病,有多种亚型。细胞毒性 T 淋巴细胞抗原-4 抗体治疗相关的垂体炎的描述是首例由药物引起的垂体炎的描述之一。随着这种新型癌症治疗方法的应用越来越多,我们必须提高对免疫相关不良反应及其治疗的认识。垂体自身免疫是一个具有挑战性的领域,有多项发现有助于进一步了解疾病并协助诊断。目前报道的方法敏感性和特异性不足,无法推荐将抗垂体抗体的检测作为垂体炎诊断的常规检查。垂体炎的治疗仍存在争议,建议从激素替代治疗到新描述的治疗方法,如硫唑嘌呤和放疗。